## Communicating diagnosis and how to deal with results: Addressing the needs of patients, families, and healthcare professionals













Neuromuscular Diseases (ERN EURO-NMD)



Pediatrician and Geneticist

SMA Research Coordinator Hospital Sant Joan de Deu,
Esplugues de Llobregat, Barcelona
Head Research group VHIR Medicine Genetics
Campus Valle Hebron, Barcelona, Spain
ERNs- ITHACA,NMD, Cranio, Bond
Member Steering Committee European Alliance for
SMA Newborn Screening















### Disclosures

- Grant support to conduct clinical trials on SMA from Ionis/Biogen
- Serves as a consultant to AveXis, Novartis, Biogen, Biologix, Cytokinetics, Roche
- Serves as a scientific/medical advisor for non profit organizations such as FAME Chile, Famiglie SMA Italy, Familias SMA Argentina, ASEM Federation, FUNDAME, SMA Europe, TREAT-NMD, EURORDIS, IFSBH

#### Rare diseases



- Low prevalence
- Rare diseases affect around 6-8% of the worldwide population
- Over 300 million people worldwide / over 3 million in Spain
- 7,000 conditions
- 80% genetic origin















### **HOW IS GENETICS IN CLINICAL PRACTICE?**

#### **HOW IS GENETICS IN CLINICAL PRACTICE?**



E Tizzano Area Genetica Clinica y Molecular Hospital Vall d'Hevbron





#### **Medical Genetics**

#### **Clinical Genetics**

Detects malformations and dysmorphia and its implications
Recognizes common genetic entities and specific syndromes
Interact with other specialists for diagnosis, follow-up, treatments
Collaborate in the development of advanced therapies

#### **Genetic Counselling**


Know the types of inheritance and the concepts and processes of genetic counseling, including communication with the patient and adaptation to a certain condition in the family and the importance of correctly reporting and giving advice regarding the results obtained in genetic tests


## Laboratory Genetics

Perform genetic tests:
Chromosome studies
Array CGH
Number of copies
Sanger sequencing
Massive (NGS) sequencing
Interprets data from
genetic and genomic
studies

A complete approach to the genetic problem of the patient and the family

### Main tasks when facing a new person with a genetic disorder





## Communication of the diagnosis **ORGANISM New patient** SOCIAL **PSYCHE ENVIROMENT Treatment** Integral decision-making follow-up


Consider three main aspects of an individual

The three main tasks include communication of diagnosis, integral follow-up and decision making of treatment that as a whole should consider a balance in the three main aspects of an individual: organism, psyque and social environment

#### The first task

#### Communicating the diagnosis






Need time to assimilate the diagnosis<sup>2</sup>

Will not retain all the information provided<sup>2</sup>

Denies of the disease is usually the first reaction<sup>3</sup>



## Genetic information: peculiarities



It is a very hard emotional situation, with family implications and many new concepts and information to assimilate

## What is genetic counseling?

Genetic counseling is a **communicative process** that addresses the human problems associated with the **risk** of occurrence or recurrence of a genetic disease in a family.



Evolution of genetics



Health perception

## Genetic information: peculiarities

Characteristics of genetic information



Potentially stressful and distressing





Direct implications for **family** members

Lifetime genetic condition

**Pre-symptomatic** diagnoses or predictions of susceptibility to pathologies **Complexity** of information (inheritance, risk, penetrance)

The stress and anxiety caused by the possibility of a genetic alteration in the family makes understanding even more difficult

#### What is genetic counseling in the context of communication of diagnosis?

Comprehension of medical concepts.



- Interpretation of family and medical histories to assess the chance of disease occurrence or recurrence.
- Education about inheritance, testing, management, prevention, resources and research.
- Choose the most apprint riate action based on risk, available options and ethical and/or religious principles.
- In case of undergoing a **genetic stude** counseling prior to the study (implications, advantages and limitations), post-test counseling.

Facilitate decision making and act in accordance with the made decision.

## Genetic counseling process



Obtain medical histories to determine genetic risks



Inform about the disease (features, natural history, genetic and environmental factors...)



Assess and communicate risks



Explain clinical implications (management, reproductive options...)




Genetic testing



Provide support throughout the whole process, support in decision making

#### PATIENT / FAMILY

#### PROFESSIONAL HEALTHCARE




Issues and attitudes of the patient/family when communicating diagnosis and alternatives to be conducted/approached by the healthcare professional responsible for the process of communication


#### The second task


Integral follow-up



Moving from traditional monographic consultation towards implementation of integrated and multidisciplinary clinics with the collaboration of case Managers







Monographic consultation

S Specialist

Interdisciplinary clinics

Multidisciplinary clinics






#### Scenarios of communication of the diagnosis in rare disorders Primary prevention Secondary prevention Tertiary prevention Pregnancy Heterozygous Presymptomatic Becoming symptomatic Becoming symptomatic Becoming symptomatic carrier screening Paucisymptomatic False negative in NBS Long diagnostic odyssey Long diagnostic odyssey Congenital Preconcep-Newborn Infant Adolescent Adult Prenatal tional Reproductive choices Reproductives choices Initial diagnosis Transition optimization Adult follow-up protocol Pediatric follow-up protocol Pediatric follow-up protocol Review of protocols In utero therapy (?) Scenarios of follow-up and therapeutic considerations

#### The third task

Decision making for treatment

- Consensus for follow-up and treatment<sup>1</sup>
- Managing expectations of the patients and the family / caregivers<sup>1,2</sup>






Figure 2 Logand. The processes to be accounted by health professionals facing a new nations. New nations may be detected at

# MANAGING EXPECTATIONS WHEN THERE IS A DIAGNOSIS AND A POSSIBLE TREATMENT

Patients give importance to the emotional impact of the experience of receiving medical care.



Consider the different perspectives of patients/family/caregive rs and physicians<sup>2</sup>



Report on data
limitations in some
cases and the
importance of standards
of care<sup>1,3</sup>



Achieving consensus on outcomes that are meaningful to the patient<sup>4</sup>



Create confidence in the multidisciplinary team<sup>4,5</sup>

CAUTION: Patients may encounter inaccurate information or information directed at patients in other countries where medical care may be different.

<sup>1.</sup> Tizzano EF, Finkel RS. Neuromuscul Disord. 2017;27:883-9. 2. Lorenzetti RC, et al. Am Fam Physician. 2013;87:419-25.

<sup>3.</sup> Wang CH, et al. J Child Neurol. 2007;22:1027-49. 4. Rovira et al. in preparation . 5. Nunlist MM, et al. Fam Pract Manag. 2016;23:21-4.

## Levels of prevention in genetic disordsers

**HEALTH COSTS** 



Treat all patients with manifesting disease

Tertiary prevention

Mainly influence in standard of care and evolving phenotypes



Secondary prevention

Primary prevention

Treat all pre-symptomatic cases detected through newborn screening

Mainly influence in burden and development of the disease

Genetic counseling in all carriers detected through population screening

Mainly influence in the incidence and prevalence

SMA, spinal muscular atrophy.

<sup>1.</sup> Serra-Juhe C and Tizzano EF. Perspectives in genetic counseling for spinal muscular atrophy in the new therapeutic era: early pre-symptomatic intervention and test in minors. Eur J Hum Genet . 2019.





www.journals.elsevier.com/genetics-in-medicine-open

#### REVIEW

# The diagnosis communication process in spinal muscular atrophy: A cross-cutting view of the new challenges facing the therapeutic era



Eulàlia Rovira-Moreno<sup>1,2</sup>, Anna Abulí<sup>1,2</sup>, Patricia Muñoz-Cabello<sup>1,2</sup>, Marta Codina-Solà<sup>1,2</sup>, Eva Baillès<sup>3</sup>, Mencía de Lemus<sup>4</sup>, Basil T. Darras<sup>5</sup>, Eduardo F. Tizzano<sup>1,2,\*</sup>

#### > Latest News

# WHEN LANGUAGE IS A BARRIER



Applications launch for Open Academy Schools 2025

EURORDIS – Rare Diseases Europe has launched applications for the 2025 Open Academy Schools, ushering in an exciting new era...

Date: September 23, 2024



EURORDIS Open Academy expands language offerings

The EURORDIS Open Academy is proud to announce the expansion of its e-learning courses to offer programmes in Spanish, French,...

Date: September 13, 2024

# EDUCATIONAL INITIATIVE FOR PATIENTS WITH RARE DISORDERS AT HOSPITAL VALL HEBRON SINCE 2017 in SPANISH







#### ORIGINAL ARTICLE



## Beyond the disease itself: A cross-cutting educational initiative for patients and families with rare diseases

Eulàlia Rovira-Moreno<sup>1,2</sup> | Anna Abuli<sup>1,2</sup> | Marta Codina-Sola<sup>1,2</sup> | Irene Valenzuela<sup>1,2</sup> | Clara Serra-Juhe<sup>1,2</sup> | Ivon Cuscó<sup>1,2</sup> | Mar Borregán<sup>1</sup> | Anna Cueto-González<sup>1,2</sup> | Teresa Vendrell<sup>1</sup> | Fermina López-Grondona<sup>1</sup> | Carme Brun-Gasca<sup>3</sup> | Eduardo Brignani<sup>4</sup> Laia Martínez-Ribot<sup>1</sup> | Regla Garci-Espejo<sup>4</sup> | Jordi Cruz<sup>4</sup> | Elena García-Arumí<sup>1,5</sup> | Eduardo F. Tizzano<sup>1,2</sup>

#### Correspondence

Eduardo F. Tizzano, Department of Clinical and Molecular Genetics, Hospital Vall d'Hebron, 08035 Barcelona, Spain. Email: etizzano@vhebron.net

Present address

#### Abstract

Rare diseases (RDs) as a whole affect a huge number of individuals although each specific condition comprises a low number of individuals. As a consequence, funds allocated to expand research to all conditions are often limited. Several initiatives have emerged to invest more resources for research in RDs, but patients express unmet needs regarding educational initiatives, awareness support, and psychosocial resources. We developed an educational training program in the format of weekly sessions covering basic medical scientific knowledge and psychosocial aspects of RDs. The aim of this initiative was to assess its overall impact regarding knowledge, psychological issues, and participant satisfaction. Items were evaluated through surveys before and after the sessions. Here, we report the experience and impact of two editions of this initiative with a total of 37 participants. Our results show improvements in knowledge and better management of the psychological impact. Moreover, participants were able to exchange experiences and concerns, most of which were shared even though the RDs were different. Overall, the program was evaluated by

<sup>&</sup>lt;sup>1</sup>Department of Clinical and Molecular Genetics, Hospital Vall d'Hebron, Barcelona, Spain

<sup>&</sup>lt;sup>2</sup>Medicine Genetics Group, Vall d'Hebron Research Institute (VHIR), Barcelona, Spain

<sup>&</sup>lt;sup>3</sup>Department of Clinical and Health Psychology, Universidad Autónoma de Barcelona, Cerdanyola del Vallès, Spain

<sup>&</sup>lt;sup>4</sup>Federación Española de Enfermedades Raras, Delegación de Cataluña, Barcelona, Spain

Neuromusuclar Disorder and Mitochondria Research Group, Vall d'Hebron Research Institute (VHIR), Barcelona, Spain



THANK YOU FOR YOUR ATTENTION!

Questions???